Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity

Hagit Achdout, Einat. B. Vitner, Boaz Politi, Sharon Melamed, Yfat Yahalom-Ronen, Hadas Tamir, Noam Erez, Roy Avraham, Shay Weiss, Lilach Cherry, Erez Bar-Haim, Efi Makdasi, David Gur, Moshe Aftalion, Theodor Chitlaru, Yaron Vagima, Nir Paran & Tomer Israely

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic. The continued spread of SARS-CoV-2 increases the probability of influenza/SARS-CoV-2 coinfection, which may result in severe disease. In this study, we examine the disease outcome of influenza A virus (IAV) and SARS-CoV-2 coinfection in K18-hACE2 mice. Our data indicate enhanced susceptibility of IAV-infected mice to developing severe disease upon coinfection with SARS-CoV-2 two days later. In contrast to nonfatal influenza and lower mortality rates due to SARS-CoV-2 alone, this coinfection results in severe morbidity and nearly complete mortality. Coinfection is associated with elevated influenza viral loads in respiratory organs. Remarkably, prior immunity to influenza, but not to SARS-CoV-2, prevents severe disease and mortality. This protection is antibody-dependent. These data experimentally support the necessity of seasonal influenza vaccination for reducing the risk of severe influenza/COVID-19 comorbidity during the COVID-19 pandemic.
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed serious threats to global health and economy. The COVID-19 pandemic presents a broad spectrum of severities, ranging from asymptomatic presentation to severe pneumonia. Most of the mildly to critically affected patients show respiratory complications, including moderate to severe pneumonia, which can further progress to acute respiratory distress syndrome, sepsis, and multiple organ dysfunction in severely ill patients. Most of these clinical symptoms are associated with the respiratory system, specifically the lungs, resulting in the depleted lung functionality. Several risk factors for severe COVID-19 disease, such as the age, sex, and obesity have been identified. However, more research is needed to better understand the involvement of these and other risk factors in severe illness or complications. Whether coinfection with other pathogens may impact disease severity is yet to be elucidated. Previous studies have reported coinfections between SARS-CoV-2 and common respiratory viruses, including rhinovirus, inaryenavirus, metapneumovirus, parainfluenza virus, and respiratory syncytial virus. A meta-analysis of 30 studies including 9384 patients with COVID-19 revealed that overall, 7% of hospitalized patients with COVID-19 had a bacterial coinfection, while the pooled proportion of viral coinfections was 3%, with respiratory syncytial virus and influenza A virus (IAV) being the most common. However, the prevalence and disease outcomes of viral coinfecctions in the SARS-CoV-2-positive population remain controversial.

IAV is a leading cause of respiratory infection, resulting in respiratory disease. Complications involving secondary infections with other pathogens, mostly bacteria, significantly exacerbate the risk of severe disease due to IAV and other viral respiratory pathogens.

However, whether coinfection with IAV and SARS-CoV-2 presents more severe disease than a single infection is not clear. In this study, we delineate the interplay between IAV and SARS-CoV-2 infections. For this purpose, we employ transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) under control of the human cytokeratin 18 promoter (K18-hACE2 mice) to establish a SARS-CoV-2-susceptible murine model. We show that IAV-infected mice have enhanced susceptibility to developing severe disease upon coinfection with SARS-CoV-2 two days post influenza infection (dpii). In contrast to nonfatal influenza disease and lower rates of mortality due to SARS-CoV-2 alone, this coinfection is associated with elevated influenza viral loads in respiratory organs, while SARS-CoV-2 viral load was reduced following coinfection. Remarkably, prior immunity to influenza, but not to SARS-CoV-2, prevents severe disease and mortality. Finally, we show that this protection is antibody dependent.

Results and discussion

Severe mortality in K18-hACE2 mice coinfected with SARS-CoV-2 and IAV. To delineate the interplay between IAV and SARS-CoV-2 infections, we used K18-hACE2 mice to establish a SARS-CoV-2-susceptible murine model. Non/partially lethal viral doses were chosen for each virus to allow us to distinguish more severe outcomes of coinfection. The doses were determined based on challenge experiments in which K18-hACE2 mice were infected with different doses of mouse-adapted IAV (A/Puerto Rico/8/1934 H1N1 (PR8)) or SARS-CoV-2 (Supplementary Fig. 1). To mimic coinfection, the mice were infected with IAV and subsequently infected with SARS-CoV-2. While the terms ‘coinfection’ and ‘superinfection’ are often used interchangeably, the use of ‘coinfection’ here refers to a sequential infection with two viruses within a very short time, with the second infection occurring prior to the elimination of the first virus.

First, the outcome of SARS-CoV-2 infection was tested two dpii during the presymptomatic stage of influenza (Supplementary Fig. 1a). At this stage, mice do not present any disease manifestations, but the viral titer of IAV in the lungs is high. The IAV-infected mice started losing weight at 5 dpi and exhibited maximal morbidity at 9–10 dpi (75% of their initial body weight) (Fig. 1a). At 11 dpi, all the mice began to gain weight and returned to their initial body weight by 18 dpi. Remarkably, the mice infected with SARS-CoV-2 at two dpii exhibited earlier and increased weight loss compared to the mice with IAV infection alone. Moreover, in contrast to the survival and only 38% mortality of the only IAV- and only SARS-CoV-2-infected mice, respectively, all coinfected mice died by 5–7 days post SARS-CoV-2 infection (dpii) (Fig. 1b, ***p < 0.0001).

Subsequently, we examined coinfection with SARS-CoV-2 at five dpii during the early symptomatic stage. The IAV-infected and coinfected mice started to lose weight at 6-7 dpii (Fig. 1c). However, while the IAV-infected mice reached their maximal weight loss at 8 dpi (79% of their initial weight), the coinfected mice continued to lose weight until 10 dpii (73% of their initial weight). Additionally, the recovery period of the coinfected mice was prolonged compared to that of the IAV-infected mice. While the IAV-infected mice reached 97% of their initial weight at 11 dpi, the coinfected mice reached 94% of their initial weight by 17 dpii and returned to their baseline weight only 22 dpiii (Fig. 1c). Moreover, coinfection with SARS-CoV-2 at 5 dpiii resulted in 70% mortality compared to the 43% mortality observed among the mice infected with SARS-CoV-2 alone (p = 0.08) (Fig. 1d).

Finally, we assessed coinfection when SARS-CoV-2 was administered in the late-symptomatic stage of influenza disease during which maximal morbidity was detected (8 dpii, Fig. 1e, f). Interestingly, SARS-CoV-2 infection at 8 dpiii had no effect on the body weight or survival rate of the mice. These results suggest that infection with SARS-CoV-2 early upon infection with IAV results in a more severe disease, while a later SARS-CoV-2 infection has no severe effect.

In the human population, coinfection is most likely to occur during the asymptomatic period. Additionally, during the asymptomatic stage of influenza disease, as represented by the experiments with SARS-CoV-2 infection at 2 dpiii (Fig. 1a, b), coinfection resulted in the most severe and lethal disease. Therefore, we chose to focus on this stage, and hereafter, coinfection refers to infection with IAV followed by infection with SARS-CoV-2 two days later.

Increased IAV and decreased SARS-CoV-2 viral loads in coinfect ed mice. To correlate the severe outcome observed in the coinfected mice and the viral load, the IAV and SARS-CoV-2 viral loads were quantified in the lungs, nasal turbinates (N.T.), and brains (Fig. 2). A significant increase in the IAV RNA levels was observed in the lungs of the coinfected mice at 4 dpiii, but not at 6 dpiii, compared to those in the mice with IAV infection (4.6-fold increase). In the N.T., a significant increase in the IAV viral titer was observed at both 4 and 6 dpiii (11-fold and 2.3-fold increases, respectively) in the coinfected mice compared to that in IAV-infected mice (Fig. 2b, c), which coincided with the exacerbated disease. In contrast, the SARS-CoV-2 load was reduced in the coinfected mice compared to that in the SARS-CoV-2-infected mice in both the lungs and the N.T. (albeit nonsignificantly) at 4 and 6 dpiii (Fig. 2d, e). These findings are consistent with previous evidence of pathogenic competition between respiratory viruses, such as influenza and seasonal coronaviruses.

A possible explanation for the reduced SARS-CoV-2 viral load might be the induction of the innate immune response activated by the IAV.
infection prior to the SARS-CoV-2 infection, inhibiting the establishment of infection and replication.\textsuperscript{19–21.} In addition to innate immunity mechanisms underlying the reduced SARS-CoV-2 viral load, IAV infection may interfere with SARS-CoV-2 infection in vivo. Our data contradict those of a recent study showing that coinfection with IAV enhances SARS-CoV-2 infectivity.\textsuperscript{22} In this previous study, no significant differences were found in disease manifestations between coinfected K18-hACE2 mice and SARS-CoV-2-monoinfected mice. However, the SARS-CoV-2 infection dose in our study is 4-log lower than that in the Bai et al.’s study, and no data comparing coinfection and IAV-monoinfected mice were presented by Bai et al., making comparison between the two studies difficult.

Notably, although the SARS-CoV-2 viral load was reduced in the coinfected mice, the remaining levels were sufficient to trigger the lethal outcome of the coinfection.

Fig. 1 Morbidity and mortality in K18-hACE2 mice infected with SARS-CoV-2 following influenza infection. K18-hACE2 mice were infected with IAV (80 PFU/mouse, i.n.), followed by infection with SARS-CoV-2 (10 PFU/mouse, i.n.) at 2 (a, b), 5 (c, d), or 8 (e, f) dpi. The percent weight loss following infection is shown (a, c, e). The red arrow represents IAV infection. The blue arrow represents SARS-CoV-2 infection. All measurement data are expressed as mean ± standard error (SE). The area under the curve (AUC) was calculated using GraphPad Prism 8.4.3; IAV infection compared to coinfection (a, c, e); ****p < 0.0001 (a, c, e); ns (e). Survival curves are shown (b, d, f); *p = 0.0453; ***p = 0.0007; ****p < 0.0001; IAV or SARS-CoV-2 infection compared to coinfection. ns, not significant (p = 0.0779), log-rank test (Mantel-Cox). The figure shows one representative experiment of 4 (a, b), 2 (c, d), and 1 (e, f) experiments performed. The figure includes the IAV-infected group, which consisted of 10 (a, b), 11 (c, d), or 8 (e, f) mice; the SARS-CoV-2-infected group, which consisted of 13 (a, b) or 14 (c–f) mice; and the coinfection group, which consisted of 11 (a, b), 10 (c, d), or 7 (e, f) mice.
Histopathological analysis of coinfected K18-hACE2 mice. Lung pathology was observed in all infected groups and was consistent with the IAV viral load, with the coinfected mice presenting the most severe pathology (Fig. 2g); the lungs of the IAV-infected mice appeared moderately to strongly affected, showing necrosis of the bronchiolar epithelium with massive peribronchiolar infiltration of neutrophils and lymphocytes (Fig. 2g). The SARS-CoV-2-infected lungs showed milder histological changes characterized by minor-to-mild interstitial infiltration of lymphocytes and some neutrophils, with no obvious necrosis (Fig. 2g). The lungs of the coinfected mice showed a histopathological pattern similar to that observed in the IAV group but were more severe, including involvement of the lung parenchyma. Small hemorrhages were observed in the interstitium of some samples, and thickening of the pleura was identified in 3 of 5 animals (Fig. 2g). Taken together, these results
suggest that the increased morbidity and mortality detected in the coinfected mice are associated with elevated levels of IAV and exacerbated pathology in the respiratory system.

K18-hACE2 mice are a valuable model of SARS-CoV-2 infection and have been studied extensively\(^23,24\). However, in K18-hACE2 mice, SARS-CoV-2 also enters the brain, which might affect the disease severity\(^15\). To examine whether the increased morbidity was brain related, SARS-CoV-2 viral load was measured in brain tissues, and was found in only 3 of 10 SARS-CoV-2-infected mice (Fig. 2f; at 4 dpSi). Importantly, no virus was detected in the brains of the coinfected mice, and no brain pathology was apparent at 4 dpSi (Supplementary Fig. 2).

Coinfection in AdV-hACE2 mice model. Subsequently, to exclude the possibility that the severe outcome of the coinfected mice is model specific and brain related, we examined an additional independent COVID-19 mouse model, i.e., hACE2-expressing human Ad5 (AdV-hACE2) mice. In the AdV-hACE2 model, C57BL/6J mice were inoculated via the intranasal (i.n.) route with replication-defective adenovirus encoding the hACE2 receptor, resulting in lung-specific pathology\(^25\). Similar to the K18-hACE2 mice, the AdV-hACE2 mice were significantly more sensitive to coinfection with SARS-CoV-2 at 2 dpii (Supplementary Fig. 3). While all monoinfected mice survived the infection, only 9% of the coinfected mice survived (Supplementary Fig. 3). These results support that coinfection lethality is not model specific.

Uprolagement of inflammation-related genes in the lungs of coinfected mice. To elaborate upon the host response to each monoinfection versus coinfection, we assessed the expression of immune-related genes in the lungs at 4 dpii and 2 dpSi.

The genes tested can be divided into the following groups: the complement system (C1ra, C1rb, C3, and C1s1); antigen presentation (H2-eb1 and H2-k1); recruitment and activation of immune cells (Cd2, Fas, Cd38, Gzma, and Prf1); interleukins (Il1a and Il6); chemokines (Ccl5, Ccl8, Ccl12, and Cxcl10); interferon response (Ifi44, Ifi11, Ifi3, Ifi27l2a, and Irf7); matrix metalloproteinases (Mmps); tissue damage (Mmp3, Mmp8, Mmp9, and Timp1); and a member of the Slfn family (Sfl9d), the ubiquitin-like modifier Isg15, and Z-DNA-binding protein 1 (Zbp1).

Overall, in the lungs of the SARS-CoV-2-infected mice, no alterations in the mRNA levels of the tested genes were observed compared to those in the lungs of the uninfected mice (Fig. 3) most likely due to the low infection dose (10 PFU/mouse) and short time post infection (2 days). After the infection with IAV, all tested genes were overexpressed (Fig. 3). Remarkably, the IAV and SARS-CoV-2 coinfection resulted in a significantly larger elevation of gene expression than exhibited upon IAV infection alone, indicating robust induction of the immune system that may have led to exacerbated disease.

Preexisting immunity to SARS-CoV-2 does not rescue coinfected mice. Then, we examined whether preexisting immunity to SARS-CoV-2 prevents the severe manifestations in the coinfected mice. Efficient immunity to SARS-CoV-2 was achieved by intramuscular (i.m.) immunization of SARS-CoV-2 (Supplementary Fig. 4a, b). This route of immunization induced both humoral and cellular responses (Supplementary Fig. 4a, b, respectively) against SARS-CoV-2 and was sufficient to protect the mice from a SARS-CoV-2 challenge (Fig. 4a-c). However, while preexisting immunity to SARS-CoV-2 completely prevented the mortality caused by SARS-CoV-2 infection, accounting for 50%, it had no effect on the morbidity and full mortality caused by the IAV and SARS-CoV-2 coinfection (Fig. 4b, c). To rule out the possibility that the inability of SARS-CoV-2 immunization to rescue the coinfected mice was a result of the i.m. immunization route, we examined another SARS-CoV-2 route of immunization. The acquisition of preexisting immunity to SARS-CoV-2 by the i.n. route (Supplementary Fig. 4c, d) did not protect the mice from coinfection (Supplementary Fig. 5), which is similar to the results of infection via the i.m. route, even though both routes of infection induced humoral and cellular responses to SARS-CoV-2 (Supplementary Fig. 4).

Prior immunity to IAV protects coinfected K18-hACE2 mice. To determine whether preexisting immunity to IAV can prevent coinfection manifestations, mice were vaccinated i.m. with IAV 30 days prior to the viral infection with IAV and/or SARS-CoV-2. This preexposure to IAV induced both humoral and cellular responses (Supplementary Fig. 6a, b, respectively) against IAV and alleviated the morbidity observed upon infection with IAV (Fig. 4f). Preexposure to IAV had no effect on the survival rate upon SARS-CoV-2 infection (Fig. 4e, p = 0.64). Remarkably, immunity to IAV prevented the severe manifestations and mortality caused by the IAV and SARS-CoV-2 coinfection. Neither weight loss nor increased mortality was detected in the coinfected mice vaccinated against IAV compared to those in the coinfected mice without preexisting immunity (Fig. 4e, f).

These data further support the notion that the severe manifestations of coinfection are not the result of a more severe SARS-CoV-2 disease but rather of IAV.

Prior immunity to IAV rescues coinfected mice and is antibody dependent. Next, we examined whether the protection of coinfected mice by prior immunization is due to cellular or humoral immunity. First, T-cell depletion was conducted (Supplementary Fig. 7). Mice were immunized by the i.m. route to IAV to induce immunity; after 30 days, CD4\(^+\) or CD8\(^+\) T cells were depleted, the mice were coinfected with IAV and SARS-CoV-2, and the ability of preexisting immunity to rescue the mice in the presence or absence of T cells was tested (Fig. 4g, h). The depletion of CD4\(^+\) or CD8\(^+\) T cells had no effect on the survival rate of the preimmune coinfected mice. This result suggests that the protection provided by preimmunity to IAV is T cell independent. Next, to delineate the role of anti-IAV
Fig. 3 Panel of inflammation-related genes with increased expression in the lungs of coinfected mice. Expression of various inflammation-related genes in the lungs. RNA was isolated from the lungs of K18-hACE2 mice at 4 dpI/2 dpS and analyzed by real-time qRT-PCR. Each symbol represents one mouse (4 per group). The Y axis represents the fold change in the infected mice compared with the naive mice. The column height represents the mean. The error bars represent the SE. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.00002 Student’s t-test two tailed, Microsoft Excel 2016.
antibodies in the protection of coinfected mice, we performed passive transfer of anti-IAV sera to coinfected mice. Anti-IAV antibodies rescued the coinfected mice (Fig. 4i), indicating that the protection was indeed antibody dependent.

Altogether, our data show that IAV-SARS-CoV-2 coinfection results in severe and lethal disease in mice. The severe manifestations were associated with an elevated IAV viral load, robust induction of innate immunity, and exacerbated pathology in respiratory organs. Importantly, prior humoral immunity to influenza, but not to SARS-CoV-2, prevented disease and mortality, suggesting that influenza intervention by prior vaccination may prove valuable in reducing the risk of severe influenza/SARS-CoV-2 comorbidity.
Methods

Cells. Vero E6 cells (ATCC® CRL-1586TM) and Madin-Darby canine kidney (MDCK) cells (ATCC® CCL-34™) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), MEM non-essential amino acids, 2 mM L-glutamine, 100 units/ml penicillin, 0.1 mg/ml streptomycin and 12.5 units/ml nystatin (Biological Industries, Israel). The cells were cultured at 37 °C in a 5% CO2 and 95% air atmosphere.

Viruses. The SARS-CoV-2 isolate human 2019-nCoV ex China strain BarPat1/ 2020 was kindly provided by Prof. Dr. Christian Drosten (Charité, Berlin) through the European Virus Archive – Global (EVAG Ref:SKU: 026-V-03883). The viral stocks were propagated (4 passages) and titrated in Vero E6 cells. The genome sequence has been deposited at the GISAID EpiCov coronavirus SARS-CoV-2 platform database under the identifier EPI_ISL_383826.

IAV strain A/Puerto Rico/8/1934 (H1N1) (PR8) was prepared by injecting 0.1 ml of a 1:100 diluted viral stock (2048 hemagglutination units, HAUs) into the allantoic sac of 11-day-old embryonated chicken eggs. After incubation for 72 h at 37 °C, ~9 ml of virus-rich allantoic fluid was collected. The HAU value was determined using chicken erythrocytes, and virus titers were determined by plaque assay using MDCK cell monolayers. Ad-GFP-hACE2 (code ADV-200183) was purchased from Vector Biosystems Inc. (Malvern, PA, USA).

All animals were viruless and stored at ~80 °C until use.

Animal experiments. All animal experiments involving SARS-CoV-2 were conducted in a biosafety level 3 (BSL3) facility. The animal handling was performed in accordance with the regulations outlined in the U.S. Department of Agriculture (USDA) Animal Welfare Act and the conditions specified in the Guide for Care and Use of Laboratory Animals (National Institutes of Health, 2011). The animal studies were approved by the ethical committee for animal experiments of the Israel Institute for Biological Research (IIBR) (protocol numbers M-29-20, M-39-20, M-40-20, M-41-20, M-42-21, M-37-21). For the IAV-hACE2 transgenic mice (Bi. C. LLC-K18-ACE2290), C57BL/6J female and male C57BL/6J mice (Jackson Laboratory) (6 months old) were randomly assigned to the experimental groups. Female and male C57BL/6J mice (Jackson Laboratory) (6 weeks old) were maintained at 20 °C and a relative humidity of 50 ± 10% under a 12-hour light/dark cycle. The mice were fed commercial rodent Chow (KoFolk Inc.) and provided tap water ad libitum. Prior to infection, the mice were kept in groups of 10. The mice were randomly assigned to the experimental groups.

For the PR8 and SARS-CoV-2 infection, the viruses were diluted in phosphate-buffered saline (PBS) supplemented with 2% FBS (Biological Industries, Israel). Anesthetized animals (ketamine 75 mg/kg and xylazine 7.5 mg/kg in PBS) were infected by i.n. instillation of 20 μl (PR8: 80 PFU/mouse, SARS-CoV-2: 10 PFU/mouse).

For the infection with Ad-GFP-hACE225, C57BL/6J mice were injected intraperitoneally (i.p.) with 2 mg of an anti-IFNAR (interferon-α/β receptor) monoclonal antibody (mAb) (LEINCO Technologies, Inc., St. Louis, MO, USA, code L-401-100) in 0.5 ml. After 24 h, 20 μl of Ad-GFP-hACE225 were administered to the anesthetized mice. After 3 days, the mice were treated i.n. with 80 PFU of PR8, and after 2 days, the mice were treated i.n. with 107 PFU of SARS-CoV-2 (all i.n. administrations were performed under anesthesia).

Animal immunization. For the SARS-CoV-2 immunization, i.n. instillation of 2 PFU/mouse or i.m. injection of 104, 105, 106, or 107 PFU/mouse SARS-CoV-2 was performed. For the IAV immunization, the mice were vaccinated i.m. with 10^6 PFU/mouse. The immunized mice were infected 30 days post immunization.

Detection of the viral load in organs. The viral loads were determined at 2 and 4 dpi for 4 and 6 dpi. In the infected group, the viral load was determined at 4 and 6 dpi (2 and 4 dpi). Each group included 10 mice, except for the experiments examining brains at 2 dpi, which included a group of 4 K18-hACE2 animals. The lungs, N.T., and brains were harvested and stored at ~80 °C until further processing. The organs were processed for fixation in 1.5 ml of ice-cold PBS. Tissues were homogenized (ULT-TRAX® IKA R104) for 30 s in 1.5 ml of ice-cold PBS, followed centrifugation (270g, 10 min, 4 °C) and collection of the supernatants for virus titration. Processed tissue homogenates were divided for immediate RNA extraction for the IAV RNA determination and gene expression analysis or kept at ~80 °C until further processing for the viral titration (used for SARS-CoV-2 FFU assay).

The SARS-CoV-2 viral load was determined using a FFU assay27. Serial dilutions of extracted organ homogenates from mice infected with SARS-CoV-2 or coinfected with IAV and SARS-CoV-2 were prepared in infection medium (MEM containing 2% FBS) and used to infect Vero E6 monolayers in duplicate (200 μl/well). The plates were incubated for 1 h at 37 °C to allow viral adsorption. Then, 2 ml overlay (MEM containing 2% FBS and 0.4% tragacanth; Merck, Israel) were added to each well, and the plates were incubated at 37 °C in a 5% CO2 atmosphere for 48 h. The medium was then aspirated, and the cells were fixed and stained with 1 ml/well crystal violet solution (Biological Industries, Israel). The number of plaques per well was determined, and the SARS-CoV-2 FFU titer was calculated.

The IAV RNA level was determined using real-time RT-PCR (see below).

Quantitative real-time RT-PCR. RNA was extracted with a viral RNA mini kit (Qiagen, Germany) according to the manufacturer’s instructions. The IAV RNA loads in the lung and N.T. were determined by quantitative RT-PCR (qRT-PCR). Relative SARS-CoV-2 was conducted by Bio-PlexSASSant PAS™ (Bio-Rad, Hercules, CA, USA) and analyzed with a 7500 Real-Time PCR System (Applied Biosystems). The FFU value per organ (pFU/organ) was calculated from a standard curve generated from virus stocks. The quantitative PCR (qPCR) primers and probes were used for the detection of PR8 were PR8-PA-FW: CGCTGGCAATCTTCTGTTGA; PR8-PA-RW: CCATTTGCTCTCCATCCAT; and PR8-PA-Probe: CAAAGCTCTAGGGAGGAAGGATCCTGAG.

Total RNA extracted from the lungs of mice infected with IAV or SARS-CoV-2 or coinfected at 2 dpi and 4 dpi were used to measure the differential expression of genes by qRT-PCR using corresponding specific primers printed on 96-well plates (Custom TaqMan Array Plates, Applied Biosystems) as previously described28 Briefly, 1 μg of cDNA was synthesized from RNA using a Verso cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. The samples were subjected to qPCR with TaqMan® Fast Advanced Master Mix (7500 Real-Time PCR System, Applied Biosystems).

Histopathology. For the hematoxylin and eosin (H&E) general histopathology evaluation, 6 dpi (4 dpi) mice (n = 5 per group) were anesthetized and then perfused transcardially with PBS, followed by 4% paraformaldehyde. The lungs and brains were isolated and fixed in 4% paraformaldehyde at room temperature for 2 weeks. The fixed tissues were sent to ‘Patho-Logica’ (Rehovot, Israel) for processing and analysis. Serial coronal 4 μm thick sections were obtained, and selected sections were stained with H&E for light microscopy examination. Pictures were taken using an Olympus microscope (BX60, serial No. 7D04032) equipped with a microscope camera (Olympus DP73, serial No. OH5504) at objective magnifications of X4 and X10.

Plaque reduction neutralization test. The SARS-CoV-2-neutralizing antibody levels were determined using a plaque reduction neutralization test (PRNT)29 Briefly, all sera were heat inactivated at 60 °C for 30 min, then serially diluted twofold in 400 μl of infection medium, mixed with 400 μl of 300 PFU/ml SARS-CoV-2, and incubated at 37 °C in an atmosphere of 5% CO2 for 1 h. Then, 200 μl of each serum/virus mixture was added in duplicate to Vero E6 monolayers, and the cells were incubated for 1 h at 37 °C. A virus mixture without serum was used as a control. Two milliliters overlay was added to each well, and the plates were incubated at 37 °C in a 5% CO2 atmosphere for 48 h. The medium was then aspirated, and the cells were fixed and stained with 1 ml/well crystal violet solution. The number of plaques per well was determined, and the serum dilution that neutralized 50% of the virions (NT50) was calculated using Prism software (GraphPad Software Inc.).

ELISpot assays. For the detection of IFNγ-secreting cells from mice immunized with SARS-CoV-2 or IAV, the mice were sacrificed 7 or 25 days post immunization, respectively. The spleens were dissociated in GentleMACS C-tubes (Miltenyi Biotec),
filtered, separated on Ficol-Paque (GE), and washed with medium. Then, 4 × 10^5 cells from each sample were plated into 96-well ELISPot plates in duplicate in the presence of peptides representing H-2Kb immunodominant epitopes at a final concentration of 2 µg/ml and incubated at 37 °C for 24 h. The naive samples consisted of pools from 2 mice. The frequency of IFNγ-secreting cells was determined using a Mouse IFNγ Single-Color ELISPot kit (Cellular Technology Limited, Germany) according to the manufacturer’s instructions. The frequency of cytokine-secreting cells was quantified with an ImmunoPlex® Stx Ultimate reader and analyzed with ImmunoPlex® software (Cellular Technology Limited, Germany). The following Db-restricted antigens were used for the stimulation: influenza PR8-derived peptide: NP366–374 ASNENMETM SARS-CoV-2-derived peptide: Spike 539–546 VFNFNFLG

For all assays, antigen-free cells supplemented with medium were used as a negative control.

Enzyme-linked immunosorbent assay. Nunc MaxiSorp enzyme-linked immunosorbent assay (ELISA) plates (Thermo Fisher Scientific, USA) were coated with PR8 virus (white virus, sucrose purified) in carbonate/bicarbonate solution (Sigma, Israel Cat. C3841) at 4 °C overnight. Plates were blocked with TSTA buffer (50 mM Tris, pH 7.6 + 140 mM NaCl + 0.05% Tween 20 + 2% BSA) for 60 min at 37 °C. Following blocking and washing with PBST buffer (PBS + 0.05% Tween 20), the plates were incubated with a naive or PR8 preimmune mouse serum diluted from 1:400 to 1:52,800 for 1 h at 37 °C. Following washing, alkaline phosphatase-conjugated anti-mouse IgG was used (diluted 1:1000) as a secondary antibody (Sigma, Israel, cat. A5153). P-nitrophenyl phosphate substrate (Sigma, Israel, cat. N2770) was added after washing, and the optical density was measured (SpectraMax 190 microplate reader, Molecular Devices, Sunnyvale, CA, O.D. at 405 nm) after 60 min of incubation at room temperature. The anti-PR8 IgG values were determined by subtracting twice the value of the control (sera from naive mice) from the examined sample.

In vivo T cell depletion. Rat anti-mouse CD4 (clone GK1.5, ATCC TIB-207) and CD8 (clone 2.43, ATCC TIB-210) antibodies were produced and purified in our laboratory. Anti-CD4 or anti-CD8 antibodies were administered (200 µg per i.p. injection) to K18-hACE2 mice 1 day (–1 day) before viral infection and every 2–3 days during the first 12 days of the experiment. The CD4 or CD8 depletion was verified by flow cytometry (Supplementary Fig. 7).

Flow cytometry. Splenocytes were collected as described for the ELISPot assay. The cells were stained with Aqua Live/Dead Cell Stain (Thermo Fisher, L34966), blocked with an anti-CD16/32 FcγR antibody for 15 min and subsequently stained with fluorescently labeled antibodies for 30 min. The following antibodies from eBioscience (Thermo Fisher Scientific) were used: PE anti-CD4 (clone 145-2C11, diluted 1:200), Alexa Fluor 700 anti-CD8 (clone RM4-5, diluted 1:800), and APC anti-CD12 (clone 56.6–67, diluted 1:800). All washing procedures were performed using flow buffer composed of PBS, 2% BSA and 0.05% NaN3. The samples were collected using a Fortessa Flow Cytometer (BD Biosciences) and analyzed with FlowJo software (TreeStar).

Passive immunization. Six to eight-week-old female K18-hACE2 mice were immunized against IAV by i.m. injection of PR8 (10^6 PFU/mouse). Four weeks later, sera were collected and pooled, and the levels of anti-PR8 IgG antibodies in the anti-IAV sera were determined. The sera were administered (i.p. 200 µl/mouse) 1 day prior to infection with IAV. Mice were coinfected as described above.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. The data that support the findings of this study are available from the corresponding author upon reasonable request. Source data are provided with this paper.

Received: 6 July 2021; Accepted: 16 September 2021; Published online: 05 October 2021

References

1. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
2. Islam, A. B. M. K. & Khan, M. A.-A.-K. Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy. Sci. Rep. 10, 19395 (2020).
3. Regina, J. et al. Epidemiology, risk factors and clinical course of SARS-CoV-2 respiratory co-infections: Incidence of viral and bacterial co-pathogens. Int. J. Infect. Dis. 105, 617–620 (2021).
4. Lai, C.-C., Wang, C.-Y. & Hsueh, P.-R. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J. Microbiol. Immunol. Infect. 53, 505–512 (2020).
5. Peci, A. et al. Prevalence of co-infections with respiratory viruses in individuals investigated for SARS-CoV-2 in Ontario, Canada. Viruses 13, 130 (2021).
6. Musuua, J. S. et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS ONE 16, e0251170 (2021).
7. Centers for Disease Control and Prevention. Infections: Incidence of viral and bacterial co-pathogens. Available from: https://www.cdc.gov/flu/about/burden/index.html (2020). Accessed 11 Jun 2021.
8. McCullers, J. A. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat. Rev. Microbiol. 12, 252–262 (2014).
9. Falsey, A. R. et al. Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. J. Infect. Dis. 208, 432–441 (2013).
10. Laurie, K. et al. Evidence for viral interference and cross-reactive protective immunity between influenza B virus lineages. J. Infect. Dis. 217, 548–559 (2018).
11. Marangou, A. et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat. Commun. 11, 6122 (2020).
12. Nowakowska, P. et al. Pathogenicity of different PR8 influenza A virus variants in mice is determined by both viral and host factors. Virolology 412, 36–45 (2011).
13. Nickbakhsh, S. et al. Virus–virus interactions impact the population dynamics of influenza and the common cold. Proc. Natl Acad. Sci. USA 116, 27142–27150 (2019).
14. Wolff, G. G. Influenza vaccination and respiratory virus infection among Department of Defense personnel during the 2017–2018 influenza season. Vaccine 38, 350–354 (2020).
15. Rigby, R. E., Wise, H. M., Smith, N., Digard, P. & Rewinkel, J. PA-X antagonises MAVS-dependent accumulation of early type I interferon messenger RNAs during influenza A virus infection. Sci. Rep. 9, 7216 (2019).
16. Felgenhauer, U. et al. Inhibition of SARS-CoV-2 by type I and type III interferons. J. Biol. Chem. 295, 13958–13964 (2020).
17. McAfee, M. S., Huynh, T. P., Johnson, J. L., Jacobs, B. L. & Blattman, J. N. Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity. Virology 484, 153–162 (2015).
18. Bai, L. et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 31, 395–403 (2021).
19. Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327–1335 (2020).
20. Zheng, J. et al. COVID-19 treatments and pathogenesis including anesthesia in K18-hACE2 mice. Nature 589, 603–607 (2021).
21. Hassan, A. O. et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182, 744–753.e744 (2020).
22. Achdout, H. et al. Enhanced recognition of human NK receptors after influenza virus infection. J. Immunol. 171, 915–923 (2003).
23. Yahalom-Ronen, Y. et al. A single dose of recombinant VSVG-D Spike vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 11, 6402 (2020).
24. Isaely, T. et al. Differential response following infection of mouse CNS with virulent and attenuated vaccinia virus strains. Vaccines 7, 19 (2019).

Acknowledgements. The authors would like to thank Prof. Dr. Christian Drosten at the Charité University Hospital, Institute of Virology, Berlin, Germany, for providing the SARS-CoV-2 Bw-Pat1/2020 strain. We thank Dr. Michal Mandelboim for IAV/Puerto Rico/8/34 H1N1 (PR8). We thank Dr. Ofer Cohen (IIIB) for help with the AdV-hACE2 model.

Author contributions. H.A., E.B.V., R.P., and T.I. designed the research. H.A., E.B.V., B.P., S.M., R.A., H.T., Y.Y.R., N.E., L.C., M.A., Y.V., D.G., E.M., N.P., and T.I. performed the experiments. H.A., E.B.V., B.P., S.M., R.A., H.T., H.A., E.B.H., Y.G., and T.I. contributed in technical support. H.A., E.B.V., N.P., and T.I. wrote the manuscript. S.W., T.C., and E.B.H. contributed in technical support. All authors discussed the results and commented on the manuscript before submission. R.A. is supported by the Israel Science Foundation (grant 521/18). E.B.V. is supported by the Katurz Foundation.

Competing interests. The authors declare no competing interests.
Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-26113-1.

Correspondence and requests for materials should be addressed to Tomer Israely.

Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021